Fund Holdings — ACUTA CAPITAL PARTNERS, LLC

Total Portfolio Value:
$147.29M
Total Bought:
$58.10M
Total Sold:
$29.05M
Net Transaction:
+$29.04M
Securities
▲▼
SharesValue
Q3 2025
▲▼
Q4 2025
▲▼
Change
▲▼
Q3 2025
▲▼
Q4 2025
▲▼
Weight (%)
▲▼
Change
▲▼
Terns Pharmaceuticals Inc502,797637,095+134,298$3.78M$25.74M17.48%+$21.96M
Praxis Precision Medicines, Inc.(PRAX)49,75183,036+33,285$2.64M$24.47M16.62%+$21.84M
Cidara Therapeutics Inc141,52989,145-52,384$13.55M$19.69M13.37%+$6.14M
Ocular Therapeutix, Inc.(OCUL)1,165,2061,052,995-112,211$13.62M$12.78M8.68%-$837.9K
Whitehawk Therapeutics, Inc.(WHWK)3,410,4023,410,4020$6.48M$8.25M5.60%+$1.77M
Bright Minds Biosciences Inc.(DRUG)84,87584,477-398$5.15M$6.59M4.48%+$1.44M
Compass Therapeutics, Inc.(CMPX)840,0901,093,300+253,210$2.94M$5.87M3.99%+$2.93M
Jazz Pharmaceuticals plcSHS USD(JAZZ)25,11429,008+3,894$3.31M$4.93M3.35%+$1.62M
Insmed Incorporated(INSM)38,59225,878-12,714$5.56M$4.50M3.06%-$1.05M
argenx SEADR(ARGX)6,3794,851-1,528$4.70M$4.08M2.77%-$625.4K
Surrozen, Inc.(SRZN)178,415178,4150$2.30M$4.03M2.74%+$1.73M
Amylyx Pharmaceuticals, Inc.(AMLX)333,258333,2580$4.53M$4.03M2.73%-$503.2K
Minerva Neurosciences, Inc.(NERV)0709,500+709,500$0$2.85M1.94%+$2.85M
Tango Therapeutics, Inc.(TNGX)0282,732+282,732$0$2.51M1.70%+$2.51M
Taysha Gene Therapies, Inc.(TSHA)454,827454,8270$1.49M$2.50M1.70%+$1.01M
Zymeworks Inc.(ZYME)80,14380,1430$1.37M$2.11M1.43%+$741.3K
Oculis Holding AG(OCS)101,777101,7770$1.79M$2.03M1.38%+$243.2K
Design Therapeutics, Inc.(DSGN)0150,906+150,906$0$1.42M0.96%+$1.42M
Inhibrx Biosciences, Inc.(INBX)16,37716,3770$551.6K$1.29M0.88%+$742.2K
United Therapeutics Corporation(UTHR)2,2962,2960$962.5K$1.12M0.76%+$156.2K
Verastem, Inc.(VSTM)143,446143,4460$1.27M$1.11M0.75%-$159.2K
Maze Therapeutics, Inc.(MAZE)020,000+20,000$0$828.6K0.56%+$828.6K
MoonLake ImmunotherapeuticsCL A(MLTX)059,280+59,280$0$781.3K0.53%+$781.3K
Sutro Biopharma, Inc.(STRO)067,451+67,451$0$780.4K0.53%+$780.4K
Dianthus Therapeutics, Inc.(DNTH)25,00016,708-8,292$983.8K$688.5K0.47%-$295.2K
Revolution Medicines, Inc.(RVMD)8,4118,4110$392.8K$669.9K0.45%+$277.1K
LB Pharmaceuticals Inc(LBRX)30,00030,0000$473.7K$667.8K0.45%+$194.1K
Pasithea Therapeutics Corp.(KTTA)0450,000+450,000$0$580.5K0.39%+$580.5K
Unicycive Therapeutics, Inc.(UNCY)59,98559,9850$261.5K$346.1K0.23%+$84.6K
Nuvation Bio Inc.W EXP 07 07 2027(NUVB)90,83290,8320$18.4K$30.0K0.02%+$11.6K
Ascendis Pharma A/SADR(ASND)9,7920-9,792$1.95M$0—-$1.95M
Cogent Biosciences, Inc.(COGT)102,9070-102,907$1.48M$0—-$1.48M
Fulcrum Therapeutics, Inc.(FULC)57,1410-57,141$525.7K$0—-$525.7K
Krystal Biotech, Inc.(KRYS)10,5730-10,573$1.87M$0—-$1.87M
Tourmaline Bio Inc268,4510-268,451$12.84M$0—-$12.84M
Page 1 of 1
ACUTA CAPITAL PARTNERS, LLC — 13F Holdings — Q4 2025 | TickerTrail